Edition:
United States

Ritter Pharmaceuticals Inc (RTTR.OQ)

RTTR.OQ on NASDAQ Stock Exchange Capital Market

3.03USD
15 Jun 2018
Change (% chg)

$0.02 (+0.66%)
Prev Close
$3.01
Open
$2.99
Day's High
$3.03
Day's Low
$2.96
Volume
9,576
Avg. Vol
19,757
52-wk High
$7.48
52-wk Low
$1.90

Chart for

About

Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company's segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and... (more)

Overall

Beta: --
Market Cap(Mil.): $14.97
Shares Outstanding(Mil.): 4.94
Dividend: --
Yield (%): --

Financials

  RTTR.OQ Industry Sector
P/E (TTM): -- 240.92 34.18
EPS (TTM): -4.28 -- --
ROI: -77.94 -5.87 13.17
ROE: -140.54 -7.71 15.15

BRIEF-Ritter Pharmaceuticals Q1 Loss Per Share $0.41

* RITTER PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

May 15 2018

BRIEF-Ritter Pharmaceuticals Announces 1-For-10 Reverse Stock Split

* RITTER PHARMACEUTICALS ANNOUNCES 1-FOR-10 REVERSE STOCK SPLIT

Mar 22 2018

BRIEF-Ritter Pharmaceuticals Reports Q4 Loss Per Share $0.11

* RITTER PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Mar 19 2018

BRIEF-Ritter Pharmaceuticals Reports Microbiome Data From Phase 2B Study Of RP-G28 Promotes Beneficial Adaptation Of The Gut Microbiome

* RITTER PHARMACEUTICALS REPORTS MICROBIOME DATA FROM PHASE 2B STUDY OF RP-G28 PROMOTES BENEFICIAL ADAPTATION OF THE GUT MICROBIOME

Mar 12 2018

BRIEF-Ritter Pharma Board Approves 1-For-10 Reverse Stock Split

* RITTER PHARMACEUTICALS, INC.’S BOARD APPROVES 1-FOR-10 REVERSE STOCK SPLIT Source text for Eikon: Further company coverage:

Mar 01 2018

Earnings vs. Estimates